Richard J Lessells1,2, Graham S Cooke3, Nuala McGrath4,5,6,7, Mark P Nicol8,9,10, Marie-Louise Newell11, Peter Godfrey-Faussett1. 1. 1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom. 2. 2 Africa Health Research Institute, KwaZulu-Natal, South Africa. 3. 3 Division of Infectious Diseases, Imperial College London, London, United Kingdom. 4. 4 Africa Health Research Institute, School of Nursing and Public Health, University of KwaZulu-Natal, KwaZulu-Natal, South Africa. 5. 5 Academic Unit of Primary Care and Population Sciences. 6. 6 Department of Social Statistics and Demography, and. 7. 7 Research Department of Epidemiology and Public Health, University College London, London, United Kingdom. 8. 8 Division of Medical Microbiology and. 9. 9 Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and. 10. 10 National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa. 11. 11 Global Health Research Institute, Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Abstract
RATIONALE: Point-of-care (POC) diagnostics have the potential to reduce pretreatment loss to follow-up and delays to initiation of appropriate tuberculosis (TB) treatment. OBJECTIVES: To evaluate the effect of a POC diagnostic strategy on initiation of appropriate TB treatment. METHODS: We conducted a cluster-randomized trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB. Two-week time blocks were randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a district hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic. All participants provided two sputum specimens: one for the Xpert test and the other for culture as a reference standard. The primary outcome was the proportion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB treatment within 30 days. MEASUREMENTS AND MAIN RESULTS:Between August 22, 2011, and March 1, 2013, 36 two-week blocks were randomized, and 1,297 individuals were enrolled (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had culture-positive PTB. The proportions of participants with culture-positive PTB initiated on appropriate TB treatment within 30 days were 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1). The median time to initiation of appropriate treatment was 7 days (laboratory) versus 1 day (POC). CONCLUSIONS: POC positioning of the Xpert test led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems. Clinical trial registered with www.isrctn.com (ISRCTN 18642314) and www.sanctr.gov.za (DOH-27-0711-3568).
RCT Entities:
RATIONALE: Point-of-care (POC) diagnostics have the potential to reduce pretreatment loss to follow-up and delays to initiation of appropriate tuberculosis (TB) treatment. OBJECTIVES: To evaluate the effect of a POC diagnostic strategy on initiation of appropriate TB treatment. METHODS: We conducted a cluster-randomized trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB. Two-week time blocks were randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a district hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic. All participants provided two sputum specimens: one for the Xpert test and the other for culture as a reference standard. The primary outcome was the proportion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB treatment within 30 days. MEASUREMENTS AND MAIN RESULTS: Between August 22, 2011, and March 1, 2013, 36 two-week blocks were randomized, and 1,297 individuals were enrolled (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had culture-positive PTB. The proportions of participants with culture-positive PTB initiated on appropriate TB treatment within 30 days were 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1). The median time to initiation of appropriate treatment was 7 days (laboratory) versus 1 day (POC). CONCLUSIONS: POC positioning of the Xpert test led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems. Clinical trial registered with www.isrctn.com (ISRCTN 18642314) and www.sanctr.gov.za (DOH-27-0711-3568).
Authors: Douglas Wilson; Victoria Howell; Christina Toppozini; Krista Dong; Michael Clark; Rocio Hurtado Journal: J Infect Dis Date: 2011-11-15 Impact factor: 5.226
Authors: S G Schumacher; B Thangakunam; C M Denkinger; A A Oliver; K B Shakti; Z Z Qin; J S Michael; R Luo; M Pai; D J Christopher Journal: Int J Tuberc Lung Dis Date: 2015-09 Impact factor: 2.373
Authors: Peter MacPherson; Rein M G J Houben; Judith R Glynn; Elizabeth L Corbett; Katharina Kranzer Journal: Bull World Health Organ Date: 2013-11-22 Impact factor: 9.408
Authors: Kathryn Schnippel; Gesine Meyer-Rath; Lawrence Long; William MacLeod; Ian Sanne; Wendy S Stevens; Sydney Rosen Journal: Trop Med Int Health Date: 2012-06-12 Impact factor: 2.622
Authors: David W Dowdy; J Lucian Davis; Saskia den Boon; Nicholas D Walter; Achilles Katamba; Adithya Cattamanchi Journal: PLoS One Date: 2013-08-12 Impact factor: 3.240
Authors: Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol Journal: PLoS Med Date: 2014-11-25 Impact factor: 11.069
Authors: Adrienne E Shapiro; Ting Hong; Sabina Govere; Hilary Thulare; Mahomed-Yunus Moosa; Afton Dorasamy; Carole L Wallis; Connie L Celum; Jacques Grosset; Paul K Drain Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: M P Kasaro; O N Chilyabanyama; N S Shah; B Muluka; N Kapata; A Krüüner; I Mwaba; K Kaunda; W L Coggin; X J Wen; G Henostroza; S Reid Journal: Public Health Action Date: 2020-12-21
Authors: David J Lee; Nagalingeswaran Kumarasamy; Stephen C Resch; Gomathi N Sivaramakrishnan; Kenneth H Mayer; Srikanth Tripathy; A David Paltiel; Kenneth A Freedberg; Krishna P Reddy Journal: PLoS One Date: 2019-07-02 Impact factor: 3.240
Authors: Frederick Haraka; Mwaka Kakolwa; Samuel G Schumacher; Ruvandhi R Nathavitharana; Claudia M Denkinger; Sebastien Gagneux; Klaus Reither; Amanda Ross Journal: Cochrane Database Syst Rev Date: 2021-05-06